Helex Secures $3.5m Funding for Kidney Disease Therapies
Helex has raised $3.5m in a seed funding round led by pi Ventures to advance non-viral gene therapies for kidney diseases.
The company is developing programmable non-viral LNP therapies to deliver therapeutic cargo to kidney cells.
- Participation from SOSV, Bluehill Capital, and a global investor syndicate.
- Total funding now exceeds $6m.
The funding will progress its autosomal dominant polycystic kidney disease (ADPKD) lead programme.
Helex will use the funding to expand its pipeline using AI-based drug design platforms and programmable delivery.
Author's summary: Helex raises $3.5m for kidney disease therapies.
More News
- WME’s Kirk Sommer Named MUSEXPO’s ‘International Music Person of the Year’
- Cineworld announces luxury upgrade at Silverburn with new recliner seats
- East Georgia Regional Medical Center celebrates family at 5th annual Halloween Fest
- 10 tracks that prove MF DOOM was the master of samples
- Report on Waterford's public lighting network expected to be complete by early next year - News - Waterford News & Star
- 'Hotel Transylvania' spinoff 'Motel Transylvania' delayed, now set for 2027 release on Netflix | The Express Tribune
- “Rocky Horror” returns to Northern’s stage
- JD Vance and Erika Kirk’s on-stage hug goes viral amid faith and controversy debate | The Express Tribune
- Privacy laws can’t keep up with ‘luxury surveillance’
- Must-see Van Gogh exhibitions in 2026